Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Mol Genet Metab. 2016 Dec 22;120(3):247–254. doi: 10.1016/j.ymgme.2016.12.010

Figure 2. Heparan sulfate (HS-NS and HS-0S) levels in treated vs. untreated patients.

Figure 2

Untreated patients were compared with controls; treated patients were compared with untreated. A shows levels of HS-NS and B shows levels of HS-0S as mean and standard deviation. Values that were significantly increased in untreated patients or decreased by treatment are marked *p < 0.05; **p < 0.001